ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SLN Silence Therapeutics Plc

535.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 535.00 521.00 524.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Silence Therapeutics PLC Notice of Results (3199F)

20/02/2018 7:01am

UK Regulatory


Silence Therapeutics (LSE:SLN)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Silence Therapeutics Charts.

TIDMSLN

RNS Number : 3199F

Silence Therapeutics PLC

20 February 2018

Silence Therapeutics Notice of Results

London, 20(th) February 2018

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce its Preliminary Results for the twelve months ended 31st December, 2017 on Tuesday 6th March 2018.

Ali Mortazavi, Chief Executive Officer and David Ellam, Chief Financial Officer, will host a presentation for analysts at 9:00am on the day of the results at the Devonshire Club, 5 Devonshire Square, London EC2M 4YD.

Enquiries:

 
 Silence Therapeutics plc            Tel: +44 (0)20 3457 
  Ali Mortazavi, Chief Executive      6900 
  Officer 
  David Ellam, Chief Financial 
  Officer 
                                     Tel: +44 (0)20 7418 
   Peel Hunt LLP (Nominated           8900 
   Adviser and Broker) 
   James Steel/Oliver Jackson 
 Media Enquiries: 
                                       Tel: +44 (0) 20 3714 
  Optimum Strategic Communications     17 
  Mary Clark/ Eva Haas/Hollie 
  Vile 
  silence@optimumcomms.com 
 

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: http://www.silence-therapeutics.com/

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORZMGMZNLVGRZM

(END) Dow Jones Newswires

February 20, 2018 02:01 ET (07:01 GMT)

1 Year Silence Therapeutics Chart

1 Year Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

Your Recent History

Delayed Upgrade Clock